nodes	percent_of_prediction	percent_of_DWPC	metapath
Pioglitazone—SLCO1B3—Methotrexate—lymphatic system cancer	0.177	0.251	CbGbCtD
Pioglitazone—CYP2C19—Teniposide—lymphatic system cancer	0.125	0.178	CbGbCtD
Pioglitazone—CYP2C9—Teniposide—lymphatic system cancer	0.104	0.148	CbGbCtD
Pioglitazone—SLCO1B1—Methotrexate—lymphatic system cancer	0.103	0.146	CbGbCtD
Pioglitazone—CYP3A4—Cytarabine—lymphatic system cancer	0.0615	0.0875	CbGbCtD
Pioglitazone—CYP3A4—Teniposide—lymphatic system cancer	0.0606	0.0862	CbGbCtD
Pioglitazone—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0424	0.0603	CbGbCtD
Pioglitazone—CYP3A4—Vincristine—lymphatic system cancer	0.0291	0.0415	CbGbCtD
Pioglitazone—PPARG—Etoposide—Teniposide—lymphatic system cancer	0.0104	1	CbGdCrCtD
Pioglitazone—Diabetic—Methotrexate—lymphatic system cancer	0.00299	0.0104	CcSEcCtD
Pioglitazone—Hepatic failure—Fludarabine—lymphatic system cancer	0.00272	0.00946	CcSEcCtD
Pioglitazone—Cardiac failure congestive—Fludarabine—lymphatic system cancer	0.00269	0.00938	CcSEcCtD
Pioglitazone—Visual disturbance—Fludarabine—lymphatic system cancer	0.00258	0.00897	CcSEcCtD
Pioglitazone—Liver function test abnormal—Teniposide—lymphatic system cancer	0.00256	0.00893	CcSEcCtD
Pioglitazone—Cardiac failure—Fludarabine—lymphatic system cancer	0.0025	0.00871	CcSEcCtD
Pioglitazone—Cerebrovascular accident—Fludarabine—lymphatic system cancer	0.00249	0.00868	CcSEcCtD
Pioglitazone—Myocardial ischaemia—Mitoxantrone—lymphatic system cancer	0.00249	0.00867	CcSEcCtD
Pioglitazone—Accidental injury—Carmustine—lymphatic system cancer	0.00243	0.00847	CcSEcCtD
Pioglitazone—Proteinuria—Mitoxantrone—lymphatic system cancer	0.00228	0.00793	CcSEcCtD
Pioglitazone—Liver function test abnormal—Fludarabine—lymphatic system cancer	0.00225	0.00785	CcSEcCtD
Pioglitazone—Protein urine present—Mitoxantrone—lymphatic system cancer	0.00225	0.00782	CcSEcCtD
Pioglitazone—Hepatic enzyme increased—Mitoxantrone—lymphatic system cancer	0.00212	0.00737	CcSEcCtD
Pioglitazone—Angina pectoris—Fludarabine—lymphatic system cancer	0.00206	0.00716	CcSEcCtD
Pioglitazone—Sweating—Teniposide—lymphatic system cancer	0.00205	0.00715	CcSEcCtD
Pioglitazone—Vertigo—Mechlorethamine—lymphatic system cancer	0.00204	0.0071	CcSEcCtD
Pioglitazone—Bronchitis—Fludarabine—lymphatic system cancer	0.00203	0.00707	CcSEcCtD
Pioglitazone—Upper respiratory tract infection—Fludarabine—lymphatic system cancer	0.00196	0.00683	CcSEcCtD
Pioglitazone—Injury—Bleomycin—lymphatic system cancer	0.00195	0.00678	CcSEcCtD
Pioglitazone—Neoplasm—Carmustine—lymphatic system cancer	0.00195	0.00678	CcSEcCtD
Pioglitazone—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00192	0.00668	CcSEcCtD
Pioglitazone—Hyperglycaemia—Fludarabine—lymphatic system cancer	0.0019	0.00663	CcSEcCtD
Pioglitazone—Abnormal vision—Carmustine—lymphatic system cancer	0.00188	0.00654	CcSEcCtD
Pioglitazone—Acute coronary syndrome—Fludarabine—lymphatic system cancer	0.00185	0.00646	CcSEcCtD
Pioglitazone—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00185	0.00645	CcSEcCtD
Pioglitazone—Myocardial infarction—Fludarabine—lymphatic system cancer	0.00184	0.00642	CcSEcCtD
Pioglitazone—Infection—Mechlorethamine—lymphatic system cancer	0.00184	0.00641	CcSEcCtD
Pioglitazone—Urinary tract infection—Fludarabine—lymphatic system cancer	0.00183	0.00637	CcSEcCtD
Pioglitazone—Cerebrovascular accident—Bleomycin—lymphatic system cancer	0.00183	0.00636	CcSEcCtD
Pioglitazone—Skin disorder—Mechlorethamine—lymphatic system cancer	0.0018	0.00626	CcSEcCtD
Pioglitazone—Diabetes mellitus—Carmustine—lymphatic system cancer	0.0018	0.00626	CcSEcCtD
Pioglitazone—Haematuria—Fludarabine—lymphatic system cancer	0.00179	0.00625	CcSEcCtD
Pioglitazone—Sinusitis—Fludarabine—lymphatic system cancer	0.00176	0.00615	CcSEcCtD
Pioglitazone—Multiple fractures—Methotrexate—lymphatic system cancer	0.00172	0.00597	CcSEcCtD
Pioglitazone—Fracture—Methotrexate—lymphatic system cancer	0.00172	0.00597	CcSEcCtD
Pioglitazone—Injury—Carmustine—lymphatic system cancer	0.0017	0.00592	CcSEcCtD
Pioglitazone—Hypoaesthesia—Fludarabine—lymphatic system cancer	0.00168	0.00585	CcSEcCtD
Pioglitazone—Pharyngitis—Fludarabine—lymphatic system cancer	0.00168	0.00584	CcSEcCtD
Pioglitazone—Hepatic failure—Vincristine—lymphatic system cancer	0.00166	0.00578	CcSEcCtD
Pioglitazone—Polyp—Methotrexate—lymphatic system cancer	0.00164	0.00571	CcSEcCtD
Pioglitazone—Visual impairment—Fludarabine—lymphatic system cancer	0.00163	0.00567	CcSEcCtD
Pioglitazone—Cardiac failure congestive—Mitoxantrone—lymphatic system cancer	0.0016	0.00558	CcSEcCtD
Pioglitazone—Anaemia—Teniposide—lymphatic system cancer	0.00155	0.00538	CcSEcCtD
Pioglitazone—Pain in extremity—Vincristine—lymphatic system cancer	0.00149	0.00519	CcSEcCtD
Pioglitazone—Cyst—Methotrexate—lymphatic system cancer	0.00149	0.00519	CcSEcCtD
Pioglitazone—Cardiac failure—Mitoxantrone—lymphatic system cancer	0.00149	0.00518	CcSEcCtD
Pioglitazone—Malnutrition—Fludarabine—lymphatic system cancer	0.00147	0.00512	CcSEcCtD
Pioglitazone—Liver disorder—Methotrexate—lymphatic system cancer	0.00146	0.00509	CcSEcCtD
Pioglitazone—Hypertension—Teniposide—lymphatic system cancer	0.00144	0.00503	CcSEcCtD
Pioglitazone—Liver function test abnormal—Carmustine—lymphatic system cancer	0.00144	0.00502	CcSEcCtD
Pioglitazone—Chest pain—Teniposide—lymphatic system cancer	0.00142	0.00496	CcSEcCtD
Pioglitazone—Weight decreased—Bleomycin—lymphatic system cancer	0.0014	0.00487	CcSEcCtD
Pioglitazone—Oedema—Teniposide—lymphatic system cancer	0.00137	0.00475	CcSEcCtD
Pioglitazone—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00136	0.00475	CcSEcCtD
Pioglitazone—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.00136	0.00475	CcSEcCtD
Pioglitazone—Acute coronary syndrome—Bleomycin—lymphatic system cancer	0.00136	0.00474	CcSEcCtD
Pioglitazone—Anaemia—Fludarabine—lymphatic system cancer	0.00136	0.00473	CcSEcCtD
Pioglitazone—Infection—Teniposide—lymphatic system cancer	0.00136	0.00472	CcSEcCtD
Pioglitazone—Myocardial infarction—Bleomycin—lymphatic system cancer	0.00135	0.00471	CcSEcCtD
Pioglitazone—Abdominal pain upper—Mitoxantrone—lymphatic system cancer	0.00133	0.00462	CcSEcCtD
Pioglitazone—Malaise—Fludarabine—lymphatic system cancer	0.00133	0.00462	CcSEcCtD
Pioglitazone—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00132	0.0046	CcSEcCtD
Pioglitazone—Haematuria—Bleomycin—lymphatic system cancer	0.00132	0.00458	CcSEcCtD
Pioglitazone—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00128	0.00446	CcSEcCtD
Pioglitazone—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00127	0.00441	CcSEcCtD
Pioglitazone—Arthralgia—Fludarabine—lymphatic system cancer	0.00125	0.00436	CcSEcCtD
Pioglitazone—Myalgia—Fludarabine—lymphatic system cancer	0.00125	0.00436	CcSEcCtD
Pioglitazone—Discomfort—Fludarabine—lymphatic system cancer	0.00124	0.00431	CcSEcCtD
Pioglitazone—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.00123	0.00429	CcSEcCtD
Pioglitazone—Hyperglycaemia—Carmustine—lymphatic system cancer	0.00122	0.00424	CcSEcCtD
Pioglitazone—Dyspnoea—Teniposide—lymphatic system cancer	0.00122	0.00424	CcSEcCtD
Pioglitazone—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.0012	0.00418	CcSEcCtD
Pioglitazone—Oedema—Fludarabine—lymphatic system cancer	0.0012	0.00418	CcSEcCtD
Pioglitazone—Infection—Fludarabine—lymphatic system cancer	0.00119	0.00415	CcSEcCtD
Pioglitazone—Erectile dysfunction—Vincristine—lymphatic system cancer	0.00119	0.00413	CcSEcCtD
Pioglitazone—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00118	0.0041	CcSEcCtD
Pioglitazone—Urinary tract infection—Carmustine—lymphatic system cancer	0.00117	0.00408	CcSEcCtD
Pioglitazone—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.00117	0.00406	CcSEcCtD
Pioglitazone—Weight decreased—Vincristine—lymphatic system cancer	0.00117	0.00406	CcSEcCtD
Pioglitazone—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00116	0.00404	CcSEcCtD
Pioglitazone—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.00116	0.00403	CcSEcCtD
Pioglitazone—Weight increased—Mitoxantrone—lymphatic system cancer	0.00114	0.00398	CcSEcCtD
Pioglitazone—Weight decreased—Mitoxantrone—lymphatic system cancer	0.00114	0.00396	CcSEcCtD
Pioglitazone—Proteinuria—Methotrexate—lymphatic system cancer	0.00113	0.00395	CcSEcCtD
Pioglitazone—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.00113	0.00395	CcSEcCtD
Pioglitazone—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.00113	0.00394	CcSEcCtD
Pioglitazone—Myocardial infarction—Vincristine—lymphatic system cancer	0.00113	0.00392	CcSEcCtD
Pioglitazone—Feeling abnormal—Teniposide—lymphatic system cancer	0.00112	0.00392	CcSEcCtD
Pioglitazone—Protein urine present—Methotrexate—lymphatic system cancer	0.00112	0.0039	CcSEcCtD
Pioglitazone—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.0011	0.00384	CcSEcCtD
Pioglitazone—Sweating—Vincristine—lymphatic system cancer	0.0011	0.00384	CcSEcCtD
Pioglitazone—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.0011	0.00382	CcSEcCtD
Pioglitazone—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00109	0.00381	CcSEcCtD
Pioglitazone—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00109	0.00379	CcSEcCtD
Pioglitazone—Urticaria—Teniposide—lymphatic system cancer	0.00108	0.00378	CcSEcCtD
Pioglitazone—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00108	0.00375	CcSEcCtD
Pioglitazone—Sweating—Mitoxantrone—lymphatic system cancer	0.00107	0.00374	CcSEcCtD
Pioglitazone—Dyspnoea—Fludarabine—lymphatic system cancer	0.00107	0.00373	CcSEcCtD
Pioglitazone—Haematuria—Mitoxantrone—lymphatic system cancer	0.00107	0.00372	CcSEcCtD
Pioglitazone—Oedema peripheral—Carmustine—lymphatic system cancer	0.00106	0.00371	CcSEcCtD
Pioglitazone—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00106	0.0037	CcSEcCtD
Pioglitazone—Hepatic enzyme increased—Methotrexate—lymphatic system cancer	0.00105	0.00367	CcSEcCtD
Pioglitazone—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00105	0.00366	CcSEcCtD
Pioglitazone—Visual impairment—Carmustine—lymphatic system cancer	0.00104	0.00363	CcSEcCtD
Pioglitazone—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00104	0.00361	CcSEcCtD
Pioglitazone—Fatigue—Fludarabine—lymphatic system cancer	0.00103	0.0036	CcSEcCtD
Pioglitazone—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00103	0.00358	CcSEcCtD
Pioglitazone—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00102	0.00355	CcSEcCtD
Pioglitazone—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00101	0.00353	CcSEcCtD
Pioglitazone—Urethral disorder—Vincristine—lymphatic system cancer	0.00101	0.00352	CcSEcCtD
Pioglitazone—Eye disorder—Carmustine—lymphatic system cancer	0.00101	0.00352	CcSEcCtD
Pioglitazone—Hypersensitivity—Teniposide—lymphatic system cancer	0.00101	0.0035	CcSEcCtD
Pioglitazone—Hepatitis—Mitoxantrone—lymphatic system cancer	0.001	0.0035	CcSEcCtD
Pioglitazone—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.001	0.00348	CcSEcCtD
Pioglitazone—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.000997	0.00347	CcSEcCtD
Pioglitazone—Anaemia—Bleomycin—lymphatic system cancer	0.000996	0.00347	CcSEcCtD
Pioglitazone—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000989	0.00344	CcSEcCtD
Pioglitazone—Asthenia—Teniposide—lymphatic system cancer	0.000979	0.00341	CcSEcCtD
Pioglitazone—Malaise—Bleomycin—lymphatic system cancer	0.000972	0.00339	CcSEcCtD
Pioglitazone—Cardiac disorder—Vincristine—lymphatic system cancer	0.000958	0.00334	CcSEcCtD
Pioglitazone—Malnutrition—Carmustine—lymphatic system cancer	0.000941	0.00328	CcSEcCtD
Pioglitazone—Diarrhoea—Teniposide—lymphatic system cancer	0.000934	0.00325	CcSEcCtD
Pioglitazone—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00093	0.00324	CcSEcCtD
Pioglitazone—Chest pain—Bleomycin—lymphatic system cancer	0.000918	0.0032	CcSEcCtD
Pioglitazone—Myalgia—Bleomycin—lymphatic system cancer	0.000918	0.0032	CcSEcCtD
Pioglitazone—Back pain—Carmustine—lymphatic system cancer	0.00091	0.00317	CcSEcCtD
Pioglitazone—Discomfort—Bleomycin—lymphatic system cancer	0.000907	0.00316	CcSEcCtD
Pioglitazone—Neoplasm—Methotrexate—lymphatic system cancer	0.000901	0.00314	CcSEcCtD
Pioglitazone—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.000887	0.00309	CcSEcCtD
Pioglitazone—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000884	0.00308	CcSEcCtD
Pioglitazone—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00088	0.00306	CcSEcCtD
Pioglitazone—Oedema—Bleomycin—lymphatic system cancer	0.00088	0.00306	CcSEcCtD
Pioglitazone—Infection—Bleomycin—lymphatic system cancer	0.000874	0.00304	CcSEcCtD
Pioglitazone—Anaemia—Carmustine—lymphatic system cancer	0.00087	0.00303	CcSEcCtD
Pioglitazone—Back pain—Vincristine—lymphatic system cancer	0.000869	0.00303	CcSEcCtD
Pioglitazone—Asthenia—Fludarabine—lymphatic system cancer	0.000861	0.003	CcSEcCtD
Pioglitazone—Headache—Teniposide—lymphatic system cancer	0.000855	0.00298	CcSEcCtD
Pioglitazone—Back pain—Mitoxantrone—lymphatic system cancer	0.000846	0.00295	CcSEcCtD
Pioglitazone—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000832	0.0029	CcSEcCtD
Pioglitazone—Anaemia—Vincristine—lymphatic system cancer	0.00083	0.00289	CcSEcCtD
Pioglitazone—Diarrhoea—Fludarabine—lymphatic system cancer	0.000821	0.00286	CcSEcCtD
Pioglitazone—Hypertension—Carmustine—lymphatic system cancer	0.000812	0.00283	CcSEcCtD
Pioglitazone—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000812	0.00283	CcSEcCtD
Pioglitazone—Anaemia—Mitoxantrone—lymphatic system cancer	0.000808	0.00282	CcSEcCtD
Pioglitazone—Vertigo—Vincristine—lymphatic system cancer	0.000807	0.00281	CcSEcCtD
Pioglitazone—Hepatic failure—Methotrexate—lymphatic system cancer	0.000805	0.0028	CcSEcCtD
Pioglitazone—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000801	0.00279	CcSEcCtD
Pioglitazone—Chest pain—Carmustine—lymphatic system cancer	0.000801	0.00279	CcSEcCtD
Pioglitazone—Myalgia—Carmustine—lymphatic system cancer	0.000801	0.00279	CcSEcCtD
Pioglitazone—Malaise—Mitoxantrone—lymphatic system cancer	0.000789	0.00275	CcSEcCtD
Pioglitazone—Dyspnoea—Bleomycin—lymphatic system cancer	0.000784	0.00273	CcSEcCtD
Pioglitazone—Hypertension—Vincristine—lymphatic system cancer	0.000775	0.0027	CcSEcCtD
Pioglitazone—Oedema—Carmustine—lymphatic system cancer	0.000768	0.00267	CcSEcCtD
Pioglitazone—Myalgia—Vincristine—lymphatic system cancer	0.000765	0.00266	CcSEcCtD
Pioglitazone—Visual disturbance—Methotrexate—lymphatic system cancer	0.000764	0.00266	CcSEcCtD
Pioglitazone—Infection—Carmustine—lymphatic system cancer	0.000763	0.00266	CcSEcCtD
Pioglitazone—Hypertension—Mitoxantrone—lymphatic system cancer	0.000755	0.00263	CcSEcCtD
Pioglitazone—Headache—Fludarabine—lymphatic system cancer	0.000752	0.00262	CcSEcCtD
Pioglitazone—Myalgia—Mitoxantrone—lymphatic system cancer	0.000745	0.00259	CcSEcCtD
Pioglitazone—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000745	0.00259	CcSEcCtD
Pioglitazone—Chest pain—Mitoxantrone—lymphatic system cancer	0.000745	0.00259	CcSEcCtD
Pioglitazone—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.000738	0.00257	CcSEcCtD
Pioglitazone—Discomfort—Mitoxantrone—lymphatic system cancer	0.000736	0.00256	CcSEcCtD
Pioglitazone—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000733	0.00255	CcSEcCtD
Pioglitazone—Oedema—Vincristine—lymphatic system cancer	0.000733	0.00255	CcSEcCtD
Pioglitazone—Infection—Vincristine—lymphatic system cancer	0.000728	0.00254	CcSEcCtD
Pioglitazone—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000725	0.00252	CcSEcCtD
Pioglitazone—Nervous system disorder—Vincristine—lymphatic system cancer	0.000719	0.0025	CcSEcCtD
Pioglitazone—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000714	0.00249	CcSEcCtD
Pioglitazone—Oedema—Mitoxantrone—lymphatic system cancer	0.000714	0.00249	CcSEcCtD
Pioglitazone—Infection—Mitoxantrone—lymphatic system cancer	0.000709	0.00247	CcSEcCtD
Pioglitazone—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000709	0.00247	CcSEcCtD
Pioglitazone—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.0007	0.00244	CcSEcCtD
Pioglitazone—Urticaria—Bleomycin—lymphatic system cancer	0.000699	0.00243	CcSEcCtD
Pioglitazone—Insomnia—Carmustine—lymphatic system cancer	0.000695	0.00242	CcSEcCtD
Pioglitazone—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000693	0.00242	CcSEcCtD
Pioglitazone—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00069	0.0024	CcSEcCtD
Pioglitazone—Dyspnoea—Carmustine—lymphatic system cancer	0.000685	0.00238	CcSEcCtD
Pioglitazone—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000668	0.00233	CcSEcCtD
Pioglitazone—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000668	0.00233	CcSEcCtD
Pioglitazone—Insomnia—Vincristine—lymphatic system cancer	0.000663	0.00231	CcSEcCtD
Pioglitazone—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000663	0.00231	CcSEcCtD
Pioglitazone—Breast disorder—Methotrexate—lymphatic system cancer	0.000654	0.00228	CcSEcCtD
Pioglitazone—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00065	0.00227	CcSEcCtD
Pioglitazone—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000648	0.00226	CcSEcCtD
Pioglitazone—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000636	0.00222	CcSEcCtD
Pioglitazone—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000633	0.0022	CcSEcCtD
Pioglitazone—Feeling abnormal—Carmustine—lymphatic system cancer	0.000633	0.0022	CcSEcCtD
Pioglitazone—Fatigue—Vincristine—lymphatic system cancer	0.000632	0.0022	CcSEcCtD
Pioglitazone—Asthenia—Bleomycin—lymphatic system cancer	0.000631	0.0022	CcSEcCtD
Pioglitazone—Fatigue—Mitoxantrone—lymphatic system cancer	0.000615	0.00214	CcSEcCtD
Pioglitazone—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000588	0.00205	CcSEcCtD
Pioglitazone—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000581	0.00202	CcSEcCtD
Pioglitazone—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000576	0.00201	CcSEcCtD
Pioglitazone—Urticaria—Mitoxantrone—lymphatic system cancer	0.000567	0.00198	CcSEcCtD
Pioglitazone—Hypersensitivity—Carmustine—lymphatic system cancer	0.000566	0.00197	CcSEcCtD
Pioglitazone—Infestation—Methotrexate—lymphatic system cancer	0.000558	0.00194	CcSEcCtD
Pioglitazone—Infestation NOS—Methotrexate—lymphatic system cancer	0.000558	0.00194	CcSEcCtD
Pioglitazone—Asthenia—Carmustine—lymphatic system cancer	0.000551	0.00192	CcSEcCtD
Pioglitazone—Hypersensitivity—Vincristine—lymphatic system cancer	0.00054	0.00188	CcSEcCtD
Pioglitazone—Sweating—Methotrexate—lymphatic system cancer	0.000535	0.00186	CcSEcCtD
Pioglitazone—Haematuria—Methotrexate—lymphatic system cancer	0.000532	0.00185	CcSEcCtD
Pioglitazone—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000526	0.00183	CcSEcCtD
Pioglitazone—Asthenia—Vincristine—lymphatic system cancer	0.000526	0.00183	CcSEcCtD
Pioglitazone—Diarrhoea—Carmustine—lymphatic system cancer	0.000525	0.00183	CcSEcCtD
Pioglitazone—Asthenia—Mitoxantrone—lymphatic system cancer	0.000512	0.00178	CcSEcCtD
Pioglitazone—Dizziness—Carmustine—lymphatic system cancer	0.000508	0.00177	CcSEcCtD
Pioglitazone—Diarrhoea—Vincristine—lymphatic system cancer	0.000502	0.00175	CcSEcCtD
Pioglitazone—Hepatitis—Methotrexate—lymphatic system cancer	0.000501	0.00174	CcSEcCtD
Pioglitazone—Pharyngitis—Methotrexate—lymphatic system cancer	0.000497	0.00173	CcSEcCtD
Pioglitazone—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000494	0.00172	CcSEcCtD
Pioglitazone—Urethral disorder—Methotrexate—lymphatic system cancer	0.000491	0.00171	CcSEcCtD
Pioglitazone—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000488	0.0017	CcSEcCtD
Pioglitazone—Dizziness—Vincristine—lymphatic system cancer	0.000485	0.00169	CcSEcCtD
Pioglitazone—Visual impairment—Methotrexate—lymphatic system cancer	0.000482	0.00168	CcSEcCtD
Pioglitazone—Headache—Carmustine—lymphatic system cancer	0.000481	0.00168	CcSEcCtD
Pioglitazone—Eye disorder—Methotrexate—lymphatic system cancer	0.000468	0.00163	CcSEcCtD
Pioglitazone—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000465	0.00162	CcSEcCtD
Pioglitazone—Headache—Vincristine—lymphatic system cancer	0.000459	0.0016	CcSEcCtD
Pioglitazone—Immune system disorder—Methotrexate—lymphatic system cancer	0.000452	0.00157	CcSEcCtD
Pioglitazone—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000451	0.00157	CcSEcCtD
Pioglitazone—Headache—Mitoxantrone—lymphatic system cancer	0.000447	0.00156	CcSEcCtD
Pioglitazone—Malnutrition—Methotrexate—lymphatic system cancer	0.000436	0.00152	CcSEcCtD
Pioglitazone—Back pain—Methotrexate—lymphatic system cancer	0.000422	0.00147	CcSEcCtD
Pioglitazone—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000404	0.00141	CcSEcCtD
Pioglitazone—Anaemia—Methotrexate—lymphatic system cancer	0.000403	0.0014	CcSEcCtD
Pioglitazone—Malaise—Methotrexate—lymphatic system cancer	0.000393	0.00137	CcSEcCtD
Pioglitazone—Vertigo—Methotrexate—lymphatic system cancer	0.000392	0.00136	CcSEcCtD
Pioglitazone—Arthralgia—Methotrexate—lymphatic system cancer	0.000371	0.00129	CcSEcCtD
Pioglitazone—Chest pain—Methotrexate—lymphatic system cancer	0.000371	0.00129	CcSEcCtD
Pioglitazone—Myalgia—Methotrexate—lymphatic system cancer	0.000371	0.00129	CcSEcCtD
Pioglitazone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000368	0.00128	CcSEcCtD
Pioglitazone—Discomfort—Methotrexate—lymphatic system cancer	0.000367	0.00128	CcSEcCtD
Pioglitazone—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000356	0.00124	CcSEcCtD
Pioglitazone—Infection—Methotrexate—lymphatic system cancer	0.000353	0.00123	CcSEcCtD
Pioglitazone—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000349	0.00121	CcSEcCtD
Pioglitazone—Skin disorder—Methotrexate—lymphatic system cancer	0.000345	0.0012	CcSEcCtD
Pioglitazone—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000344	0.0012	CcSEcCtD
Pioglitazone—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000324	0.00113	CcSEcCtD
Pioglitazone—Insomnia—Methotrexate—lymphatic system cancer	0.000322	0.00112	CcSEcCtD
Pioglitazone—Dyspnoea—Methotrexate—lymphatic system cancer	0.000317	0.0011	CcSEcCtD
Pioglitazone—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000307	0.00107	CcSEcCtD
Pioglitazone—Fatigue—Methotrexate—lymphatic system cancer	0.000307	0.00107	CcSEcCtD
Pioglitazone—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000293	0.00102	CcSEcCtD
Pioglitazone—Urticaria—Methotrexate—lymphatic system cancer	0.000283	0.000984	CcSEcCtD
Pioglitazone—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000262	0.000913	CcSEcCtD
Pioglitazone—Asthenia—Methotrexate—lymphatic system cancer	0.000255	0.000889	CcSEcCtD
Pioglitazone—Diarrhoea—Methotrexate—lymphatic system cancer	0.000243	0.000848	CcSEcCtD
Pioglitazone—Dizziness—Methotrexate—lymphatic system cancer	0.000235	0.000819	CcSEcCtD
Pioglitazone—Headache—Methotrexate—lymphatic system cancer	0.000223	0.000776	CcSEcCtD
